Sanofi’s Dupixent (dupilumab) Receives Health Canada Approval as the First Biologic to Treat Atopic Dermatitis in Children

February 24, 2021 Auto Bot approval, Atopic Dermatitis, Children, Health Canada, receives, regulatory, Sanofi, Treatment 0

Shots:

  • Health Canada has approved Dupixent for the treatment of mod. to sev. AD in children aged 6 to 11yrs. whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
  • The approval marks the fifth indication for Dupixent in Canada following the approvals for AD in adults and adolescents, severe chronic rhinosinusitis with nasal polyposis, and severe asthma in adults and adolescents
  • The results from a survey in Canadian children showed 70% experienced the loss of sleep and 30% experienced anxiety. Dupixent is a mAb targeting IL-4 and IL-13 proteins and is not an immunosuppressant

Click here ­to­ read full press release/ article | Ref: Newswire Canada | Image: Global Competition Review

The post Sanofi’s Dupixent (dupilumab) Receives Health Canada Approval as the First Biologic to Treat Atopic Dermatitis in Children first appeared on PharmaShots.